Back to top
more

Cardinal Health (CAH)

(Real Time Quote from BATS)

$94.33 USD

94.33
572,373

+0.23 (0.24%)

Updated Jul 15, 2024 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q1 Earnings

The growing adoption of Panther instruments worldwide will likely drive Hologic's (HOLX) Q1 revenues.

Intuitive Surgical (ISRG) to Post Q4 Earnings: What's in Store?

Intuitive Surgical's (ISRG) fourth-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Will Boston Scientific (BSX) Beat Q4 Earnings Estimates?

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies.

ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues

ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Cardinal Health (CAH) Gains As Market Dips: What You Should Know

Cardinal Health (CAH) closed at $76.47 in the latest trading session, marking a +0.07% move from the prior day.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome

Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

Align Technology's (ALGN) increased shipments in Invisalign case volumes across almost all markets are likely to benefit Q4 revenues.

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

Investors continue to be optimistic about Merit Medical (MMSI), owing to its strong product portfolio.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

Intuitive Surgical (ISRG) continues to gain traction from the increasing adoption of the da Vinci Surgical System. Improving margins buoy optimism.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

BD's (BDX) New Robotic Track System to Boost Lab Workflow

BD's (BDX) new robotic track system for the BD Kiestra microbiology laboratory solution is expected to streamline lab workflows.

What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?

Within Abbott's (ABT) Established Pharmaceuticals Division (EPD), new product launches across key markets have been majorly boosting business in recent months.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

Growing adoption of Panther instruments and growth in the Surgical business will likely drive Hologic's (HOLX) Q1 revenues.

DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates

DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.

Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Intuitive Surgical (ISRG) Reports Mixed Preliminary Q4 Revenues

Intuitive Surgical's (ISRG) revenue growth in the fourth quarter is driven by increase in procedure volume, partially offset by resurgence of COVID-19 in China.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Inogen (INGN) Announces Solid Preliminary Q4 Revenues

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its product sales.

Cardinal Health (CAH) Flat As Market Gains: What You Should Know

Cardinal Health (CAH) closed at $76.52 in the latest trading session, marking no change from the prior day.

PacBio's (PACB) Preliminary Q4 Revenues Dampened by Lower Sales

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.

Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues

Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.

Nevro's (NVRO) Preliminary Q4 Revenues Solid, Issues '23 Outlook

Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.